Cristina de Min joined NovImmune in May 2010 as Chief Medical Officer. Cristina has over 15 years of experience in drug development which she matured through different leadership positions at Roche. She was responsible for the global development (phase I through IV) of a series of compounds targeting mainly autoimmune and endocrine diseases, the last one being a monoclonal antibody for the treatment of Rheumatoid Arthritis. Cristina was also Scientific Advisor to the Head of Global Development at Roche and the Head of Medical Affairs in one of the major Roche Affiliates. Prior to joining the Pharma industry, Cristina, who holds a medical degree from the University of Milan and a postgraduate degree in Endocrinology and Metabolic Diseases, was in academia where she both taught and practiced medicine.